Dr Bo Jesper Hansen Dr Bo Jesper Hansen, M.D., PhD, currently serves as Executive Chairman of the Boards of Swedish Orphan Biovitrum and TopoTarget. He is also non-Executive Director of a number of biotech and pharma companies including Orphazyme, Newron Pharmaceuticals, CMC AB, Hyperion Therapeutics and Genspera. Dr Hansen served as CEO and President and as Director to the Board of Swedish Orphan International until the acquisition of Biovitrum, forming Swedish Orphan Biovitrum. He also was Non-Executive Director of Gambro until its acquisition by Baxter, and Zymenex, until its acquisition by Chiesi. He founded Scandinavian Medical Research during which he served as Medical Advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical.